Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02989935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 18, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Mar 31, 2024 to Mar 31, 2026
    • Enrollment target: 25 to 30
    • Study completion date: Jul 1, 2024 to Jul 1, 2026
    v6
  2. Primary completion date: Jan 1, 2022 to Mar 31, 2024
    • Study completion date: May 1, 2022 to Jul 1, 2024
    v5
  3. Primary completion date: Dec 1, 2019 to Jan 1, 2022v4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: 30 to 25
    • Study completion date: Apr 1, 2020 to May 1, 2022
    • Site details revised
  4. Primary completion date: Jul 1, 2018 to Dec 1, 2019
    • Study completion date: Sep 2018 to Apr 1, 2020
    v3
  5. Primary completion date: Apr 2017 to Jul 1, 2018
    • Study completion date: Apr 2017 to Sep 2018
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Calgary
208 trials monitored
See 5 trials at risk
COPD
1,119 trials monitored
See 34 trials at risk
This study examines the effect of the ultra long acting beta agonist/corticosteroid bronchodilator combination fluticasone furoate/vilanterol trifenatate, on respiratory muscles and ventilation in adults with severe bronchitis or emphysema (COPD).
Trial Details
NCT Number NCT02989935
Lead Sponsor University of Calgary
Conditions
(from sponsor)		 Copd
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov